Argentina Gastric Cancer Treatment Market – Industry Trends and Forecast to 2030

Analyse et taille du marché du traitement du cancer gastrique en Argentine

Data Bridge Market Research analyse que le marché argentin du traitement du cancer gastrique, qui était de 58,63 millions USD en 2023, devrait atteindre 92,37 millions USD d'ici 2031 et devrait connaître un TCAC de 9,1 % au cours de la période de prévision de 2024 à 2031. « L'adénocarcinome » domine le segment de type du marché argentin du traitement du cancer gastrique en raison de la demande croissante de traitement du cancer gastrique. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché

Définition du marché

Le cancer gastrique est une maladie dans laquelle des cellules malignes (cancéreuses) se forment dans la paroi de l'estomac. L'âge, le régime alimentaire et les maladies de l'estomac peuvent influer sur le risque de développer un cancer gastrique. Les symptômes du cancer gastrique comprennent l'indigestion et l'inconfort ou la douleur à l'estomac.

Dynamique du marché du traitement du cancer gastrique en Argentine

Conducteurs

• Increase in incidence of gastrointestinal tumours, lymphoma, and adenocarcinoma

As the incidence of cancer increases, it limits the activities of daily living and requires medical attention. The technology of next-generation sequencing (NGS), PCR, and CLIA aids in providing efficient information for the proper diagnosis and prognosis of cancer. The increased incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma raises the demand for early detection and diagnosis via utilizing the latest technology thereby propelling the growth of the market.

• Rise in alcohol consumption and surge in smoking

Epidemiological, clinical, and laboratory evidence point to a behavioural relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone, and so represents a severe public health issue that warrants further investigation. A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.

Increasing alcohol consumption and smoking is creating demand for medical devices for the diagnosis of cancer, which is driving market growth.

• Increase in the geriatric population

With the growing geriatric population across the world, the prevalence of chronic diseases such as arthritis, cancer, respiratory diseases, metabolic disorders, orthopaedic, cardiovascular, and other age-related diseases is also increasing. The older population is more prone to diseases therefore there is a strong correlation between age and the causes of diseases requiring diagnosis and treatment.

Below mentioned are some of the statistics related to the increased geriatric population across the globe:

With this increasing age and rising prevalence of chronic diseases, the demand for early diagnosis of the diseases is also increasing. Also, with the growing population, the pressure on the healthcare system is increasing with which the demand for care, services, and technologies is rising to prevent and treat chronic diseases at old age. Therefore, the demand for advanced medical devices for the diagnosis of cancer is rising in the healthcare system worldwide.

Opportunities

• Rise in adoption of automated systems

Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress. Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for example, is a new field focused on multidimensional data processing. It can also benefit from AI advancements. Increased imaging diagnostic accuracy, which can be ensured by artificial intelligence algorithms that help to automate the job of radiologists and histopathologists, is a major problem in the development of technology in cancer diagnosis and treatment. Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.

• Increased research and development on cancer diagnostics products

Research & development is crucial in all industries including the healthcare Industry. The healthcare industry carries out extensive research and development not only to generate revenue but it often brings results in lives by saving or enhancing a patient's life. The drug development or biomarkers development requires random screening of active ingredients from ordinary bases and then authentication of the hits for activity in animal models to check is sifting procedure to find the few compounds in a huge set that have a desired biological activity. Pharmaceutical research and development conduct clinical trials by using different assays such as cell viability assays, cell proliferation assays, cytotoxicity assays, cell senescence assays, and cell death assays. Pharmaceutical and biopharmaceutical companies conduct a lot of clinical trials to complete successful drug or biologic, reagents, and tests development. Nowadays, healthcare companies have increased focus on research and development of cancer diagnostics which has raised the demand for gastric cancer diagnosis.  Also, across the globe, research and development activities are escalating owing to public health expenditure with economic performance.

Restraints/Challenges

• High cost of gastric cancer diagnostic test

The diagnostic tests for gastric cancer include highly technologically advanced products. The development of those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high which proportionally increases the cost of testing.

• Stringent regulations and policies for approving the complicated nature of radiation devices

Regulation of medical devices plays a significant role in healthcare. Radiation devices like CT scan, PET scan, and MRI among other are of significant importance for cancer diagnosis. But their approval and marketing require a meeting of stringent regulatory standards and approvals by various regulatory bodies. These stringent regulations and policies for approving the complicated nature of radiation devices act as a challenge for market growth.

This Argentina gastric cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Argentina gastric cancer treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2021, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers. This new drug approval of the company has increased its sales and demand in the market leading to increased sales in the future

Argentina Gastric Cancer Treatment Market Scope

The Argentina gastric cancer treatment market is segmented on the basis of type, stages, treatment, route of administration, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Adenocarcinoma
• Lymphoma
• Gastrointestinal Stromal Tumor
• Carcinoid Tumor
• Others

Stage

• Stage I
• Stage II
• Stage III
• Stage IV

Treatment

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

Route of Administration

• Oral
• Parenteral

End User

• Specialty Clinics
• Hospitals
• Research and Academic
• Institutes
• Others

Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Others

Competitive Landscape and Argentina Gastric Cancer Treatment Market Share Analysis

The Argentina gastric cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Argentina gastric cancer treatment market.

Some of the major players operating in the Argentina gastric cancer treatment market are:

• Abbott Laboratories (U.S.)
• Siemens Healthineers AG (Germany)
• Quidel Corporation (U.S.)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Danaher Corporation (U.S.)
• Becton, Dickinson and Company (U.S.)
• Chembio Diagnostics (U.S.)
• EKF Diagnostics (U.K.)
• Trinity Biotech plc (Ireland)
• Instrumentation Laboratory (a Werfen Company) (U.S.)
• Nova Biomedical (U.S.)
• PTS Diagnostics (U.S.)
• Sekisui Diagnostics (U.S.)
• Thermo Fisher Scientific (U.S.)
• bioMérieux S.A. (France)

SKU-66599